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RELN encodes a large, secreted glycoprotein integral to proper neuronal positioning
during development and regulation of synaptic function postnatally. Rare, homozygous,
null mutations lead to lissencephaly with cerebellar hypoplasia (LCH), accompanied by
developmental delay and epilepsy. Until recently, little was known about the frequency
or consequences of heterozygous mutations. Several lines of evidence from multiple
studies now implicate heterozygous mutations in RELN in autism spectrum disorders
(ASD). RELN maps to the AUTS1 locus on 7q22, and at this time over 40 distinct
mutations have been identified that would alter the protein sequence, four of which are
de novo. The RELN mutations that are most clearly consequential are those that are
predicted to inactivate the signaling function of the encoded protein and those that fall
in a highly conserved RXR motif found at the core of the 16 Reelin subrepeats. Despite
the growing evidence of RELN dysfunction in ASD, it appears that these mutations in
isolation are insufficient and that secondary genetic or environmental factors are likely
required for a diagnosis.
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Autism spectrum disorder (ASD) currently affects as many as 1 in 45 children in the
United States (Zablotsky et al., 2015). ASD incorporates Asperger, autism, and pervasive
developmental disorder-not otherwise specified (PDD-NOS), and is characterized by social,
behavioral, and language deficits. A small percentage (<20%) of ASD known as ‘‘syndromic
autism’’ is attributable to monogenetic diseases, the two most common being fragile
X syndrome and tuberous sclerosis (Miles, 2011; Persico and Napolioni, 2013). Other
monogenetic disorders that have a high frequency of ASD but are less prevalent in the general
population include Prader-Willi/Angelman, 15q microduplication, Rett, Smith-Lemli-Opitz,
and Timothy syndromes.
The remaining 80% of ASD cases are considered ‘‘non-syndromic autism’’ and are the focus of
high throughput sequencing efforts. A better understanding of how candidate genes contribute to
ASD at the molecular level is key to understanding how so many variants converge on a common
phenotype. RELN, encoding a large secreted glycoprotein, expressed in the brain and critical for
proper brain development and synapse function, is consistently cited as a candidate gene for ASD
(Persico and Napolioni, 2013).
In 2001 the International Molecular Genetic Study of Autism Consortium (IMGSAC)
described a region on chromosome 7q as the peak region of linkage and first autism
susceptibility locus (AUTS1; IMGSAC, 1998). Subsequent linkage studies supported
this finding (IMGSAC, 2001a,b; Lamb et al., 2005). Given the role of RELN in
neurodevelopment and its location at chromosome 7q22, RELN quickly emerged
as a candidate gene for autism and numerous studies (>15) have investigated the
occurrence of ASD risk-associated single nucleotide polymorphism (SNPs) in RELN
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(DeSilva et al., 1997; Persico et al., 2001; Krebs et al., 2002;
Zhang et al., 2002). These and other studies had mixed results,
possibly due to varying study designs, ethnic populations, and
mathematical interpretations. A recent meta-analysis considered
three known SNPs in RELN, and concluded that one rs362691
was significantly associated with an increased risk of ASD (Wang
et al., 2014a).
While SNP analysis supports heterozygous mutations
in RELN, it cannot explain how they contribute to ASD.
Many genes have been proposed as candidates for ASD
on the basis of sequencing analysis, but like RELN, their
pathological mechanism remains speculative. Instead of
perseverating on a particular individual SNP, researchers
are now considering candidate genes on a much broader
scale. The sum of coding and non-coding variants from
genome-wide screens coupled with network analyses, gene
and protein expression, and epigenetic modifications provide
evidence that helps understand functionally how a gene
contributes to ASD (Neale and Sham, 2004). From these
types of analyses emerges an approach for deciphering
the role of RELN in ASD at the molecular level, beyond
association.
RELN expression is both spatially and temporally consistent
with ASD, which is thought to originate as a neurodevelopmental
disorder that persists into postnatal life. Homozygous loss
of RELN leads to severe neuronal dysplasia in several
brain regions including the neocortex, hippocampus, and
cerebellum. Patients homozygous null for RELN suffer from
lissencephaly with cerebellar hypoplasia (LCH), a profoundly
developmentally debilitating disease (Hong et al., 2000; Chang
et al., 2007). Patients with LCH also suffer from epilepsy, but
no autistic behavior has been reported in the patients or their
parents.
RELN is first expressed by Cajal Retzius (CR) cells, and
other less well defined marginal zone neurons, that act as
pioneer neurons by regulating the positioning of projection
neurons into discrete layers in the neocortex (D’Arcangelo et al.,
1995; Hirotsune et al., 1995; Ogawa et al., 1995; Ikeda and
Terashima, 1997; Meyer et al., 2004). CR eventually degenerate
and a population of GABA-ergic interneurons expresses RELN
postnatally (Pesold et al., 1998). In the developing cerebellum,
RELN is first expressed by cells of the rhombic lip that
migrate to populate the external granule layer and regulate
the position of Purkinje neurons (D’Arcangelo et al., 1995;
Miyata et al., 1997). Postnatally, cerebellar granule cell neurons
(GCNs) now positioned in the internal granule layer continue to
secrete Reelin, although its postnatal role is not clear (Sinagra
et al., 2008). The brain size and architecture are relatively
normal in the heterozygous reeler mouse (HRM); however,
male HRM, thought to model ASD, have decreased numbers
of Purkinje cells (Hadj-Sahraoui et al., 1996; Biamonte et al.,
2009).
Traditionally, the cerebellum is considered responsible for
fine-tuning movement, but its role in cognitive and emotional
functions is now appreciated (Buckner, 2013). Acute adult
injury results in the classical cerebellar signs early, such
as asynergy, followed by subtle, often overlooked cognitive
and communication impairments. In contrast, damage to
the cerebellum during development leads to cognitive and
communication defects. Interestingly, these early injuries have
also been associated with the occurrence of ASD, which
highlights a role for the cerebellum in its etiology (Becker and
Stoodley, 2013; Wang et al., 2014b).
One of the most consistent anatomic findings in ASD is a
decrease in cerebellar Purkinje cells and decreased volume of
the vermis (Fatemi et al., 2012; D’Mello et al., 2015; Hampson
and Blatt, 2015). In the most recent stereologic study, Skefos
et al. (2014) found that Purkinje cells were decreased in ASD
individuals. Compared to previous studies, this group included
patients with cognitive delay and epilepsy, showing that this
defect is widespread across ASD. The role of Purkinje cells and
their ability to drive ASD behaviors as seen in tuberous sclerosis,
has been recently demonstrated in a mouse model (Tsai et al.,
2012a). They used a conditional knock-out of TSC1 in Purkinje
cells to show that dysfunction in these cells was sufficient to
decrease interest in novel mouse social interaction, increase
grooming, and increase ultrasonic vocalizations—behaviors
consistent with other ASD mouse models (Silverman et al.,
2010).
Not only is RELN expression consistent with ASD, but the
Reelin signaling pathways intersect prominent ASD protein
networks. To understand how so many disparate genes can
converge on a similar phenotype, grouping candidate genes into
networks has helped to uncover cellular processes that might be
driving ASD. Network analysis continually implicates synaptic
function and dysregulated protein translation, particularly at the
synapse (Gilman et al., 2011; Sanders et al., 2012; Ebert and
Greenberg, 2013; De Rubeis et al., 2014).
Canonical Reelin signaling is initiated by Reelin binding
its receptors very-low-density-lipoprotein receptor (VLDLR)
and apolipoprotein E receptor 2 (ApoER2; LRP8; D’Arcangelo
et al., 1999; Hiesberger et al., 1999; Trommsdorff et al., 1999).
Disabled-1 (Dab1) is recruited to the receptors, which then
activates Src family kinases and leads to reciprocal activation
through tyrosine phosphorylation of Dab1 (Howell et al.,
1997, 1999; Rice et al., 1998; Arnaud et al., 2003; Bock and
Herz, 2003). This signaling initiates a number of signaling
cascades, which have been extensively reviewed (Tissir and
Goffinet, 2003; D’Arcangelo, 2014; Sekine et al., 2014). Dab1
and VLDLR have been suggested to be associated with ASD
risk, but overall there is little evidence directly implicating
Dab1, VLDLR, ApoER2, SRC, or FYN in ASD (Fatemi
et al., 2005; Iwata et al., 2012; Li et al., 2013; Shen et al.,
2015).
Particularly relevant to ASD network analyses are recent
studies of the integral role of Reelin as a modulator of
the postnatal synapse and the ability of Reelin to enhance
LTP in the hippocampus (Weeber et al., 2002; Beffert et al.,
2005; Chen et al., 2005). Secretion of Reelin, however, is
constitutive and independent of synaptic activity (Lacor et al.,
2000). Canonical Reelin-ApoER2/VLDLR-Dab1 signaling leads
to phosphorylation of the NMDA receptor (NMDAR), increased
calcium flux with glutamate stimulation, as well as altered
intermembrane mobility of NR2B and NR2A subunit-containing
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FIGURE 1 | Autism spectrum disorders (ASD) candidate genes cluster into functional networks, and the two most prominent are synapse
structure/function and protein translational control. The Reelin-signaling pathway intersects both of these networks. Reelin binds its receptors ApoER2 and
very-low-density-lipoprotein receptor (VLDLR). The adapter protein Dab1 binds the cytoplasmic NPXY motif of the receptors and is phosphorylated by Src family
kinases. This reciprocally activates Src, which leads to phosphorylation of the NMDA receptor (NMDAR) as well as downstream AKT/PI3K signaling that intersects
the mTOR pathway.
receptors (Beffert et al., 2005; Chen et al., 2005; Groc et al.,
2007; Campo et al., 2009; Ventruti et al., 2011). Reelin is also
capable of modulating presynaptic neurotransmitter release by
regulating the VAMP7 and SNAP-25 interaction (Bal et al.,
2013).
Structurally, ApoER2, NMDAR, PTEN, and PSD-95 form
a complex at the post-synaptic density in a Reelin-dependent
manner (Ventruti et al., 2011; Figure 1). Neurexins and
neuroligins, pre- and post-synaptic cell adhesion molecules
respectively, organize the synapse, and each has been implicated
in ASD (Dean and Dresbach, 2006). Neuroligins interact
with PSD-95, which in turn is anchored to the cytoskeleton
through SHANK proteins (Ebert and Greenberg, 2013).
SHANK3 mutations often lead to Phelan-McDermid syndrome,
which frequently presents with ASD (Grabrucker et al.,
2011). PSD-95 expression is also regulated by fragile X
mental retardation protein (FMRP), the protein implicated
in fragile X syndrome (Tsai et al., 2012b). Hypermethylation
of a trinucleotide expansion leads to decreased expression
of FMRP and subsequent augmented synaptic mRNA
translation.
Reelin also directly intersects protein translation control,
the second major candidate gene network and hallmark of
Fragile X and tuberous sclerosis syndromes. Tuberous sclerosis
is caused by mutations in either TSC1 or TSC2 genes,
which leads to hyperactivation of mTORC1 and subsequent
increases in protein translation (Crino, 2011). Canonical Reelin
signaling activates Akt, which phosphorylates TSC1/2 and
leads to dendrite growth and branching (Jossin and Goffinet,
2007). Recently, Reelin and Dab1 protein expression were
shown to be increased in TSC2 conditional knock-out mice
as well as human cortical tubers (Moon et al., 2015). Here,
activation of mTOR signaling may impair Cul5-mediated Dab1
degradation. Although Reelin signaling through mTOR is still
incompletely understood, it is clear that it plays a significant
role.
Further evidence for RELN involvement in ASD is the
observation of decreased expression of RELN transcript and
encoded protein in ASD patients. Decreased Reelin was detected
in the cerebellum of ASD subjects as compared to controls
(Fatemi et al., 2001, 2005) and in the superior frontal cortex
(Fatemi et al., 2005). RELN mRNA in these areas was
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decreased, as was the dab1 transcript. VLDLRmRNA levels were
increased.
Part of the elusiveness of ASD etiology is the likelihood
of gene-environment interactions. Maternal stressors during
gestation have been shown to alter RELN expression through
promoter methylation (Giovanoli et al., 2014). MeCP2, the gene
implicated in Rett and MeCP2 duplication syndromes, which
share features of ASD, shows increased binding to the RELN
promoter in human ASD cerebella (Zhubi et al., 2014). This
binding corresponds with decreased RELN mRNA expression,
consistent with the aforementioned reduced RELN expression in
ASD tissue samples.
With the advent of more efficient and affordable sequencing
technologies, whole-exome sequencing (WES) has become
a new, popular approach for identifying candidate genes.
WES identifies probable disease-contributing mutations that
disrupt protein function. The average rate of mutation for
the human genome is 1.2 × 10−8 per nucleotide. Over the
entire genome, Kong et al. (2012) detected 63.2 de novo
mutations per trio studied, but only 2% of the human
genome is actually coding sequence (Kong et al., 2012).
Therefore, in agreement with these findings, each exome
has approximately only a single de novo protein changing
allele (Gratten et al., 2013). Focusing then on only detected
de novo events is a way to streamline candidate gene
discovery.
Initial expectations were that individuals with yet unsolved
complex disorders would have increased indels, CNVs, and
frameshift, nonsense, and missense mutations compared to
controls. While findings support that nonsense mutations may
be more frequent in ASD than controls, the general finding is
that there is not a dramatic overall increase in de novo mutation
rates in ASD (Neale et al., 2012; Sanders et al., 2012; Samocha
et al., 2014). Furthermore, de novo mutations do not make up a
large enough proportion of cases to explain the elusive genetics
of ASD, and likely represent less than 5% of the overall ASD risk
(Neale et al., 2012).
Currently more than two de novo mutations in a gene
support its candidacy, although this threshold will increase
with increasing patients to control for multiple testing. RELN
currently has four unique documented de novo ASD-associated
mutations, three of which are likely pathological (Neale et al.,
2012; De Rubeis et al., 2014; Iossifov et al., 2014; Yuen et al.,
2015). Furthermore, RELN was 1 of 22 genes with a false
discovery rate of < 0.05 in a study of nearly 4000 ASD
patients (De Rubeis et al., 2014). De novo mutations, while
directly explaining very few cases, are likely to contribute, at
least in part, to disease in the proband in whom they were
discovered. Given the repeated implication of particular gene
signaling networks in ASD, understanding how a single de novo
mutation influences this system at the molecular level will help
explain a much larger number of ASD cases (Gratten et al.,
2013).
Large and small scale WES studies of ASD individuals
consistently identify missense and nonsense mutations in RELN,
leading researchers to emphasize its importance in ASD (De
Rubeis et al., 2014). There are currently over 40 unique RELN
variants identified in ASD probands that are absent in controls
(Bonora et al., 2003; Neale et al., 2012; Koshimizu et al.,
2013; De Rubeis et al., 2014; Iossifov et al., 2014; Yuen et al.,
2015; Zhang et al., 2015; Figure 2). These mutations have
not been functionally characterized; however, strong predictions
regarding their consequences can be deduced based on Reelin
structure and function.
Reelin, a large 410 kDa protein, comprises eight Reelin repeat
domains (D’Arcangelo et al., 1995; Nogi et al., 2006; Panteri
et al., 2006; Yasui et al., 2007). Each Reelin repeat domain is
composed of two subrepeat domains (A and B) linked by an
EGF-like domain that share highly conserved sequences and
are structurally similar. Reelin binds its receptors ApoER2 and
VLDLR through two lysine residues on subrepeat 6A (Yasui et al.,
2010).
The first prediction from structure-function analysis is
that any nonsense mutation that truncates Reelin before
the receptor-binding domain will be loss-of-function. In this
instance, the transcript would either be degraded by nonsense-
mediated decay or it would produce a protein product
unable to initiate canonical signaling. Two mutations with
this characteristic have been identified—a de novo mutation
Q417X and a frameshift mutation that disrupts Reelin after
E221 (De Rubeis et al., 2014). Both of these mutations occur
before the receptor binding residues K2359 and K2466 (mouse
equivalents K2360, K2467; Yasui et al., 2010). Whether these
mutations could also contribute to a possible gain-of-function,
perhaps through a non-canonical Reelin pathway is unclear,
since the receptor-ligand domain is unknown (Lee et al.,
2014).
Alternatively, one may predict that mutations may interfere
with conserved domains, altering Reelin function in a way
that contributes to the ASD phenotype. Aligning the subrepeat
sequences of Reelin (Clustal Omega) and plotting the mutations
identified in ASD genetic studies, we have found that
Reelin is enriched in mutations that lie within an RXR
consensus sequence that occurs once in each subrepeat (Bonora
et al., 2003; De Rubeis et al., 2014; Iossifov et al., 2014;
Figure 2). Of the identified variants, seven unique mutations
fall within the RXR consensus sequence—a much larger
percentage than would be expected by chance (R1742W,
R1742Q, R2290C, R2290H, R2292C, R2639H, R2833S). R2290C,
a mutation falling within the RXR consensus sequence, was
discovered as a de novo variant originating on the paternal
chromosome (Iossifov et al., 2014). This RXR consensus region
is highly conserved across evolution, suggesting a particular
functional relevance for this region that is linked to ASD
pathogenesis.
Each subrepeat is composed of an 11-stranded beta-
jelly roll fold, and the RXR consensus sequence is found
at the beginning of the 10th beta sheet (Nogi et al., 2006).
Arginine is important structurally for hydrogen bonding with
the protein backbone (Borders et al., 1994). Disruption at
this position could compromise protein folding, exposing
the hydrophilic pore and enabling novel interactions.
Alternatively, considering that Reelin may serve as an
extracellular matrix (ECM) molecule, these closely spaced
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arginines and their neighboring tryptophan residues may
be important for glycosaminoglycan binding (Panteri et al.,
2006).
Clustering of mutations within this RXR consensus sequence
argues against random mutations leading to complete loss-
of-function. Presumably many mutations throughout the 3460
amino acids of Reelin could disrupt function. Therefore, a
mutational hotspot might suggest a particular mode of loss-of- or
gain-of-function, the details of which will need to be determined
experimentally.
Animal models of RELN mutations may ultimately be
necessary to parse out the link between RELN and ASD.
Thus far, simple loss-of-function alleles have not provided
overwhelming evidence that heterozygous RELN mutations in
the mouse produce overt or consistent behavioral phenotypes
reminiscent of ASD (Moy and Nadler, 2008). Similarly, the
human genetics of RELN mutations suggests that a second hit,
either environmental or genetic, may be necessary for ASD.
Parents of patients with LCH are heterozygous for RELN loss-
of-function alleles but do not have ASD (Hong et al., 2000;
Chang et al., 2007). Approximately half of the ASD-associated
mutations identified in RELN, including truncating and RXR
mutations, are inherited from normal parents. In addition,
following the same method of characterizing mutations in
controls from ASD studies, here too there are examples of a
nonsense mutation truncating Reelin before the receptor binding
domain (Q849X) and RXR consensus mutations (R1198H,
R2104H, and R2292H; Bonora et al., 2003; De Rubeis et al.,
2014).
Since RELN is particularly susceptible to environment-
driven epigenetic changes, one can hypothesize that perhaps
a single mutation, which decreases its expression, combined
with environmental down-regulation of Reelin production,
could drive Reelin protein levels below a critical threshold
in the brain. Or, perhaps another modifying gene allele in
trans provides this added susceptibility. One likely contributing
factor is sex. RELN mutations occur in approximately four
times as many male as female probands. And indeed,
testosterone and estrogen have differing effects on RELN
expression and HRM phenotypes (Hadj-Sahraoui et al., 1996;
Absil et al., 2003; Biamonte et al., 2009; Macri et al.,
2010).
Adding to the excitement and promise of deciphering the
role of RELN in ASD is evidence that Reelin supplementation
or increased production could potentially reverse behavioral
consequences of decreased Reelin signaling (Rogers et al., 2011,
2013; Hethorn et al., 2015). As mutations in RELN continue to
be identified in genetic studies and the molecular mechanisms
of these mutations are elucidated, we will better understand
the role of Reelin in neuronal signaling, development,
and ASD.
In the same way that science stresses transitioning from
the bench to the bedside, we must also start to move gene
candidates from the computer to the bench. RELN is now well
positioned to make such a transition in ASD research. This
approach will not be without its challenges, since it is predicted
that for RELN and many of the other candidate genes, a single
mutation may not be sufficient to cause overt ASD phenotypes,
and gene-gene or gene-environment interactions will need to be
considered.
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